Biomarker Navigator

breast cancer

4 curated biomarkers

← Back to browse

FDA-approved treatments

  • BRCA1
    • Lynparza (olaparib) [fda]
    • Talzenna (talazoparib) [fda]
  • BRCA2
    • Lynparza (olaparib) [fda]
    • Talzenna (talazoparib) [fda]
  • ERBB2
    • Perjeta (pertuzumab) [ema]
    • Herceptin (trastuzumab) [fda]
    • Enhertu (trastuzumab deruxtecan) [fda]
    • Tukysa (tucatinib) [fda]
  • PIK3CA
    • Piqray (alpelisib) [fda]
    • Itovebi (inavolisib) [fda]

Prevalence

  • BRCA1

    Pathogenic germline BRCA1 variants are found in approximately 5% of unselected breast cancers and up to 15% of ovarian cancers.[fda]

  • BRCA2

    Pathogenic germline BRCA2 variants are found in approximately 5% of unselected breast cancers and are also associated with elevated risk of ovarian, pancreatic, and prostate cancer.[fda]

  • ERBB2

    HER2 is overexpressed or amplified in approximately 15%-20% of breast cancers and approximately 15%-20% of gastric/gastroesophageal junction adenocarcinomas.[fda]

  • PIK3CA

    PIK3CA hotspot mutations are found in approximately 40% of hormone receptor-positive, HER2-negative advanced breast cancers.[fda]

Tests / detection method

  • BRCA1

    germline genetic testing, somatic NGS

  • BRCA2

    germline genetic testing, somatic NGS

  • ERBB2

    IHC, ISH/FISH, NGS (amplification calling)

  • PIK3CA

    NGS, PCR-based mutation assays

Therapeutic pipeline

Recent news for breast cancer

  • PubMed Central · Oct 1, 2026

    Combined Pathological Response and PEPI Score Improves Long-term Prognostic Stratification in HR-positive Breast Cancer Following Neoadjuvant Endocrine Therapy.

    Read at PubMed Central

  • PubMed Central · Oct 1, 2026

    Role of EMP2 and Del-1 in Tamoxifen-resistant Breast Cancer Cells.

    Read at PubMed Central

  • PubMed Central · Oct 1, 2026

    Tumor Mutational Landscape and Its Correlation With Histopathological Characteristics in Breast Cancer.

    Read at PubMed Central

  • U.S. Food and Drug Administration · Sep 4, 2026

    FDA grants accelerated approval to camizestrant with a CDK4/6 inhibitor for ESR1-Mutated HR-positive, HER2-negative locally advanced or metastatic breast cancer

    On September 4, 2026, the Food and Drug Administration granted accelerated approval to camizestrant (Etcamah, AstraZeneca), an estrogen receptor antagonist, in combination with a CDK4/6 inhibitor (abemaciclib, palbociclib, or ribociclib) for adults....

    View original at U.S. Food and Drug Administration

  • U.S. Food and Drug Administration · Sep 4, 2026

    FDA Grants Accelerated Approval to a New Breast Cancer Treatment

    The U.S. Food and Drug Administration today expanded treatment options for adult patients with advanced breast cancer, reflecting the FDA’s commitment to advancing medical innovation and getting new treatments to patients who need them.

    View original at U.S. Food and Drug Administration

  • PubMed Central · Sep 4, 2026

    How reliable is deep inspiration breath hold at CT simulation? Clinical impact of surface-guided breathing training in breast cancer radiotherapy.

    Read at PubMed Central

  • PubMed Central · Sep 4, 2026

    Role of sentinel lymph node biopsy in patients with early breast cancer undergoing mastectomy.

    Read at PubMed Central

  • PubMed Central · Sep 3, 2026

    Value of shear wave elastography in evaluating response to neoadjuvant chemotherapy in breast cancer: A systematic review and meta-analysis.

    Read at PubMed Central

  • PubMed Central · Sep 2, 2026

    M6 Metabolite Contributes to the Efficacy of the Rac/Cdc42 Inhibitor MBQ-167 in Metastatic Breast Cancer.

    Read at PubMed Central

  • PubMed Central · Sep 2, 2026

    Multi-omics integration uncovers epigenetic control of metabolic reprogramming in triple-negative breast cancer.

    Read at PubMed Central

  • PubMed Central · Sep 2, 2026

    Mapping the Subtype-Specific PARP1 ADP-Ribosylated Proteome in Breast Cancer Cells.

    Read at PubMed Central

  • PubMed Central · Sep 2, 2026

    Core components of physical activity interventions in the prevention and management of breast cancer-related lymphoedema (BCRL): A scoping review.

    Read at PubMed Central

  • PubMed Central · Sep 2, 2026

    Circulating Cell-Free DNA Methylation Profiling Enables Detection, Distinction, and Estrogen Receptor Status Classification of Advanced Breast Cancer.

    Read at PubMed Central

  • PubMed Central · Sep 2, 2026

    Ceramide-Induced Endoplasmic Reticulum Stress Reveals a Targetable Vulnerability in Endocrine Therapy-Resistant Breast Cancer.

    Read at PubMed Central

  • PubMed Central · Sep 2, 2026

    Use of indocyanine green fluorescence versus patent blue V dye for sentinel lymph node biopsy in early breast cancer, a randomized controlled trial.

    Read at PubMed Central

  • PubMed Central · Sep 2, 2026

    Effects of erector spinae plane block on postoperative pain in patients undergoing implant-based breast reconstruction for breast cancer: a randomized controlled trial.

    Read at PubMed Central

  • PubMed Central · Sep 1, 2026

    Electroacupuncture improves cognitive function and neuropsychiatric symptoms in breast cancer survivors: a pilot randomized controlled trial.

    Read at PubMed Central

  • PubMed Central · Sep 1, 2026

    Breast cancer mortality by age and race and/or ethnicity across counties in the United States, 2000-2019.

    Read at PubMed Central

  • PubMed Central · Sep 1, 2026

    Multi-omics analysis reveals comprehensive aberrant protein and phosphorylation characteristics in breast cancer and paired metastatic lymph nodes.

    Read at PubMed Central

  • PubMed Central · Sep 1, 2026

    Development of the cf-MMSP Assay for Enhanced Analytical Sensitivity of Methylated DNA in Breast Cancer Liquid Biopsy.

    Read at PubMed Central